Ide-Cel CAR T-Cell Therapy Demonstrates Promise in Heavily Pretreated Myeloma
Nina Shah, MD, discusses the potential role of idecabtagene vicleucel as treatment of patients with multiple myeloma.
Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the potential role of idecabtagene vicleucel (ide-cel; BB2121) as treatment of patients with multiple myeloma.
Ide-cel is a a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy. The original data from the phase 2 KarMMA study (NCT03361748) demonstrated a 73% overall response rate, and the rate was even higher in the 450 dose, which will be the dose moving forward. The progression-free survival was approximately 1 year, so physicians know this therapy works, especially in this heavily pretreated patient population.
